- Home
- LX vs AMPH Comparison
LX vs AMPH Comparison
Compare LX & AMPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LX
- AMPH
- Stock Information
- Founded
- LX 2013
- AMPH 1996
- Country
- LX China
- AMPH United States
- Employees
- LX N/A
- AMPH N/A
- Industry
- LX Finance: Consumer Services
- AMPH Biotechnology: Pharmaceutical Preparations
- Sector
- LX Finance
- AMPH Health Care
- Exchange
- LX Nasdaq
- AMPH Nasdaq
- Market Cap
- LX 1.3B
- AMPH 1.1B
- IPO Year
- LX 2017
- AMPH 2014
- Fundamental
- Price
- LX $7.05
- AMPH $21.70
- Analyst Decision
- LX
- AMPH Hold
- Analyst Count
- LX 0
- AMPH 5
- Target Price
- LX N/A
- AMPH $38.00
- AVG Volume (30 Days)
- LX 2.3M
- AMPH 488.2K
- Earning Date
- LX 08-26-2025
- AMPH 08-06-2025
- Dividend Yield
- LX 2.59%
- AMPH N/A
- EPS Growth
- LX 35.86
- AMPH N/A
- EPS
- LX 1.07
- AMPH 2.77
- Revenue
- LX $1,938,367,396.00
- AMPH $730,659,000.00
- Revenue This Year
- LX $2.38
- AMPH $0.67
- Revenue Next Year
- LX $8.71
- AMPH $5.18
- P/E Ratio
- LX $6.59
- AMPH $8.03
- Revenue Growth
- LX 5.63
- AMPH 8.05
- 52 Week Low
- LX $1.57
- AMPH $21.48
- 52 Week High
- LX $11.64
- AMPH $53.96
- Technical
- Relative Strength Index (RSI)
- LX 44.18
- AMPH 28.01
- Support Level
- LX $6.92
- AMPH $22.81
- Resistance Level
- LX $7.79
- AMPH $23.77
- Average True Range (ATR)
- LX 0.35
- AMPH 0.76
- MACD
- LX 0.01
- AMPH -0.20
- Stochastic Oscillator
- LX 26.24
- AMPH 9.27
About LX LexinFintech Holdings Ltd.
LexinFintech Holdings Ltd is an online consumer finance platform and a technology-driven service provider in China. The group is engaged in online direct sales services and online consumer finance services for its customers in the PRC. Geographically, it derives revenue from China.
About AMPH Amphastar Pharmaceuticals Inc.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment pharmaceutical products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.